Clinical Trial Update: Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating thalidomide to prevent or treat RCCEP induced by camrelizumab in patients with lung or esophageal cancers is ongoing with status not pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Lung Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Thalidomide (thalidomide)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Lung Cancer, Nonsmall Cell, Esophageal Carcinoma | Phase 2 | Status: UNKNOWN